Dana-Farber Clinical Research Stays on Track During COVID-19
The resilience shown by cancer care providers during the coronavirus crisis is in equal supply among those involved in clinical research.
The resilience shown by cancer care providers during the coronavirus crisis is in equal supply among those involved in clinical research.
As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders.
Sign up to subscribe to any of our e-newsletters or digital content.
